Patrys (ASX:PAB) has completed the acquisition of Reliis, marking a significant milestone in the company’s strategy to broaden its clinical-stage therapeutic pipeline with a differentiated, lower-risk asset. …
Patrys completes Reliis acquisition, expands clinical pipeline and strengthens board
January 28, 2026 Australian Biotech
Latest Video
New Stories
-
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News -
New partnership expands access to care for Australians with rare cancers
May 19, 2026 - - Latest News -
Sandoz urges faster access as government signals biosimilar consultation
May 19, 2026 - - Latest News -
Perth hosts AusMedtech conference as industry focuses on innovation and commercialisation
May 19, 2026 - - Latest News -
Government sidesteps committee call on CGMs, insulin pumps and GLP‑1 access
May 18, 2026 - - Latest News